Snowball logo
logo
AVTX

Avalo Therapeutics Inc

AVTX NASDAQ
$19.96+$0.37  (1.89%)
Estimate
EPS
-4.41
Beta
0.788
Growth
Net income, YoY
-75.09%
FCF, YoY
-58.7%
Forecast
EPS (FWD)
-2.762
About the company
Ticker
AVTX
ISIN
US05338F1084
Country
United States of America
Sector (GICS)
Healthcare
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Frequently asked questions

What sector does Avalo Therapeutics Inc (AVTX) operate in?

Avalo Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Avalo Therapeutics Inc (AVTX) current stock price?

As of the latest data, Avalo Therapeutics Inc stock price is $19.96, with a previous close of $19.59. Avalo Therapeutics Inc gained $0.37 in the last trading session, representing a 1.89% increase.

What is Avalo Therapeutics Inc (AVTX) current market capitalization?

Avalo Therapeutics Inc market cap is approximately 1.07 billion.

What is Avalo Therapeutics Inc (AVTX) Earnings Per Share (EPS)?

The trailing EPS is -$4.41, and the forward EPS is -$2.76.

What is Avalo Therapeutics Inc (AVTX) EBITDA?

Avalo Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -36.31 million.

Does Avalo Therapeutics Inc (AVTX) pay dividends?

No. Avalo Therapeutics Inc does not pay a dividend.

What is Avalo Therapeutics Inc (AVTX) beta (volatility) score?

Avalo Therapeutics Inc has a beta of 0.788, indicating lower volatility than the overall market.